Méndez Raúl, Aldás Irene, Menéndez Rosario
Pneumology Department, Hospital Universitario y Politécnico La Fe/Instituto de Investigación Sanitaria (IIS) La Fe, 46026 Valencia, Spain; Pneumology Department, Hospital Universitario y Politécnico La Fe, Avda, Fernando Abril Martorell 106, 46026 Valencia, Spain.
University of Valencia, Medicine Faculty, 46026 Valencia, Spain.
J Clin Med. 2020 Feb 18;9(2):549. doi: 10.3390/jcm9020549.
Community-acquired pneumonia (CAP) remains the first cause of morbidity and mortality worldwide due to infection. Several aspects such as severity and host response are related to its clinical course and outcome. Beyond the acute implications that the infection provokes in the host, pneumonia also has long-term negative consequences. Among them, cardiovascular complications and mortality are the most outstanding. Therefore, an adequate recognition and stratification of the risk of complications and mortality is crucial. Many biomarkers have been studied for these reasons, considering that each biomarker mirrors a different aspect. Moreover, the clinical application of many of them is still being deliberated because of their limitations and the heterogeneity of the disease. In this review, we examine some of the most relevant biomarkers that we have classified as cardiac and non-cardiac. We discuss some classic biomarkers and others that are considered novel biomarkers, which are mainly involved in cardiovascular risk.
社区获得性肺炎（CAP）仍然是全球范围内因感染导致发病和死亡的首要原因。诸如严重程度和宿主反应等多个方面与其临床病程及转归相关。除了感染在宿主中引发的急性影响外，肺炎还具有长期的负面后果。其中，心血管并发症和死亡率最为突出。因此，对并发症和死亡风险进行充分的识别和分层至关重要。出于这些原因，人们研究了许多生物标志物，因为每种生物标志物反映了不同的方面。此外，由于它们的局限性和疾病的异质性，其中许多生物标志物的临床应用仍在探讨中。在本综述中，我们研究了一些我们归类为心脏和非心脏的最相关生物标志物。我们讨论了一些经典生物标志物以及其他被认为是新型生物标志物的物质，它们主要与心血管风险有关。
